1. MIBG

    Comments Leave a Comment

    1-15 of 84 1 2 3 4 5 6 »
    1. Mentioned In 84 Articles

    2. Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site.

      ...ositive 123I-MIBG scintigraphy (3 on planar acquisitions and 6 on SPECT/CT) and 24 patients had negative 123I-MIBG scintigraphy. Five of the 6 patients (83%) with positive 123I-MIBG scintigraphy presented progressive dis...
      Read Full Article
      Mentions: Surgery Imaging MYCN
    3. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      ... was 16 ± 3%; overall survival (OS) was 27 ± 3%. Disease sites at enrollment included MIBG-avid lesions (100% MIBG trials; 84% non-MIBG trials), measurable CT/MRI lesions (48%), and BM (49%). By multivariable analysis, C...
      Read Full Article
      Mentions: Refractory NANT MYCN
    4. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

      ... was 16 ± 3%; overall survival (OS) was 27 ± 3%. Disease sites at enrollment included MIBG-avid lesions (100% MIBG trials; 84% non-MIBG trials), measurable CT/MRI lesions (48%), and BM (49%). By multivariable analysis, C...
      Read Full Article
      Mentions: Refractory NANT MYCN
    5. Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      ...vid imaging and up to 60% with relapsed and refractory neuroblastoma will require further treatment with 131I-MIBG, alternative radioisotopes have been investigated for imaging and treatment. Neuroblastoma tumors express...
      Read Full Article
    6. Comparison of diagnosing and staging accuracy of Pet (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

      ...ficity for MIBG and PET (CT) was 0.84 and 0.71, respectively. PET (CT) showed higher per-lesion accuracy than MIBG and might be the preferred modality for the staging of NB. On the other hand, MIBG has a comparable diagn...
      Read Full Article
      Mentions: Staging MIBG
    7. Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma.

      ...ur patients with persistent positive MIBG scans who underwent autologous PBSCT but experienced decreased 123I-MIBG uptake during the clinical course survived without progression, and their event-free survival (EFS) was s...
      Read Full Article
      Mentions: Treatment MIBG
    8. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      ...conducted a prospective, single-center cohort study in children with advanced neuroblastoma treated with 131I-MIBG as monotherapy or in combination with systemic putative radiation sensitizers. We collected serial periph...
      Read Full Article
    9. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome?

      ...n age 1.8 years, range 0.3-6.8 years) with newly diagnosed NB consecutively examined with pretherapeutic 123I-MIBG SPECT. Primary tumour MTV and ASP were defined using semiautomatic thresholds. Cox regression analysis, r...
      Read Full Article
      Mentions: Imaging MYCN MIBG
    10. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.

      ...d I-MIBG therapy and compared with I-MIBG posttherapy estimates. Mean ± SD whole-body doses from I-MIBG and I-MIBG scans were 0.162 ± 112 and 0.141 ± 0.068 mGy/MBq, respectively. I-MIBG and I-MIBG organ doses were variab...
      Read Full Article
    11. 1-15 of 84 1 2 3 4 5 6 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about MIBG

    1. MIBG is one of the most effective therapies available with a response rate of about 30 percent.
      In Promising High-Dose Radiation Therapy For Neuroblastoma Now Offered In Illinois